Neublastin Enters Phase I Clinical Development As A Novel Treatment For Neuropathic Pain
06 Sep 2009

NsGene A/S announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field of peripheral nervous system disorders, has entered into Phase I clinical development for the treatment of neuropathic pain.

...snip...

Neublastin is a novel and potentially disease-modifying therapeutic protein for the treatment of neuropathic pain that afflicts millions of people worldwide. Neuropathic pain is a major debilitating consequence of nerve damage and the existing treatments are largely ineffective. Neuropathic pain is commonly caused by diabetes and herpes zoster infection. Other causes are amputation, failed back syndromes, cancer-induced nerve compression and chemotherapy...
Click here to read the full article on Medical News Today's website.